Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
NCT06904755

Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

Led by Kebo Zhong · Updated on 2026-04-15

10

Participants Needed

1

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if mesenchymal stem cells in blood purification works to treat liver failure in adults. It will also learn about the safety and effectiveness of mesenchymal stem cells in blood purification. The main questions it aims to answer are:1.Does mesenchymal stem cells in blood purification improve the condition of patients with liver failure? 2.What medical problems do participants have when taking mesenchymal stem cells in blood purification? Participants will receive routine medical treatment and blood purification treatment with mesenchymal stem cells.These cells work outside the body and do not enter the body. We will: 1.Collect samples from participants such as blood, Urine and feces. 2.record post-treatment outcomes such as survival rate at 4 weeks after treatment, conversion rate to liver transplantation, Inflammatory, survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment, and liver disease indicators(prothrombin time activity percentage, lactic aicd, blood ammonia, α-fetoprotein, ferritin).

CONDITIONS

Official Title

Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age range from 18 to 65 years old
  • Patients with acute liver failure in the early and intermediate stages caused by various reasons
  • Total bilirubin (TBil) 653 171bcmol/L or an increase of 653 17.1bcmol/L per day
  • Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6)
  • No hepatic encephalopathy or encephalopathy below grade II (including grade II)
  • Elevated inflammatory markers (IL-6 / TNF-b1 / CRP, etc.)
  • Able to communicate well with researchers and complete the study
  • Must sign written informed consent before participation
Not Eligible

You will not qualify if you...

  • Severe active bleeding or diffuse intravascular coagulation
  • High allergy to blood products or drugs used during treatment such as plasma, heparin, and protamine
  • Circulatory failure
  • MELD score greater than 30
  • Severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes
  • Unable to complete the study or deemed unsuitable by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhujiang hospital

Guangzhou, Guangdong, China, 510000

Actively Recruiting

Loading map...

Research Team

K

Kebo Zhong, doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here